查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363133

药物动力学服务市场规模、份额、趋势分析报告：按药物类型、用途、最终用途、地区和细分市场预测，2023-2030 年

Pharmacokinetics Services Market Size, Share & Trends Analysis Report By Drug Type (Small Molecules), By Application (SMEs) By End-use (Biotechnology & Pharmaceutical Companies) By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

药物动力学服务市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球药物动力学服务市场规模将达到17.624亿美元，2023年至2030年年复合成长率为7.5%。

采用药物动力学和毒理学研究来确定一些参数，例如无观察到效应水平（NOEL）、人体等效剂量（HED）水平以及药物动力学/药效学（PK/PD）促进因素正在增加，预计将推动市场成长。

彻底了解潜在候选药物的药物动力学特征对于药物研发计画的成功起着重要作用。除此之外，法规机构透过制定明确的 PK 研究指导方针，在该市场的发展中发挥重要作用。有大量 CRO 根据相关 EMEA、ICH、FDA、GCP 和其他法规指南进行 PK 研究。

人们对在药物开发过程中有效实施 PK 服务的兴趣日益浓厚，预计将推动这一领域的投资。在世界各地举办了一些会议和认证课程，以提高对临床和临床前药物开发中药物动力学应用相关的各种范式的理解。

药物动力学服务市场报告亮点

  • 以药物类型来看，小分子在 2022 年占据市场主导地位，收益占有率为 76.7%，在高服务普及和仿製药日益普及的推动下，预计在预测期内将保持领先地位。
  • 由于临床阶段中存在大量生技药品和生物相似药，预计大分子的 PK 分析将在预测期内显着增长。
  • 由于美国存在大量生物製药和药品製造营业单位，2022年北美将占据最大份额。
  • 预计亚太地区在预测期内将以 9.2% 的最快年复合成长率扩张。这是因为一些国家的持续经济成长引起了全球CRO的高度关注，导致业务扩张。
  • 主要服务提供者包括 Pharmaceutical Product Development, LLC、Charles River Laboratories International, Inc.、PAREXEL International Corporation 和 Eurofins Scientific, Inc.。
  • 这些CRO正在采取各种配合措施来开拓新的市场途径并增加未来的市场份额。

目录

第1章调查方法与范围

第2章执行摘要

第3章药物动力学服务市场变数、趋势、范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 药物动力学服务市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章药物动力学服务市场：按药物类型估计和趋势分析

  • 药物动力学服务市场重点
  • 药物动力学服务市场：2022 年和 2030 年趋势和市场占有率分析
  • 低分子
  • 聚合物（生物製药）

第5章药物动力学服务市场：按用途估计和趋势分析

  • 药物动力学服务市场重点
  • 药物动力学服务市场：2022 年和 2030 年趋势和市场占有率分析
  • 中小企业
  • 大公司

第6章药物动力学服务市场：最终用途的估计和趋势分析

  • 药物动力学服务市场重点
  • 药物动力学服务市场：2022 年和 2030 年趋势和市场占有率分析
  • 生物技术和製药公司
  • 学术和政府研究机构
  • 其他的

第7章药物动力学服务市场：区域估计与趋势分析

  • 区域预测
  • 按地区分類的药物动力学服务市场：重点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第8章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Evotec AG
    • Certara, LP
    • Pacific BioLabs
    • GVK Biosciences Private Limited
    • Shanghai Medicilon Inc.
    • Pharmaceutical Product Development, LLC
    • Charles River Laboratories International, Inc.
    • PAREXEL International Corporation
    • Eurofins Scientific, Inc.
    • Frontage Labs
    • SGS SA
    • LGC Limited
    • Creative Bioarray
Product Code: GVR-2-68038-375-1

Pharmacokinetics Services Market Growth & Trends:

The global pharmacokinetics services market size is expected to reach USD 1,762.4 million by 2030, registering a CAGR of 7.5% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising adoption of pharmacokinetic and toxicology studies for determination of several parameters such as no-observed-effect levels (NOEL), human equivalent doses (HED) levels, and pharmacokinetic/pharmacodynamic (PK/PD) drivers are expected to fuel market growth.

Thorough understanding of the pharmacokinetic profile of a potential drug candidate plays a major role in the success of a drug discovery program. In addition to this, regulatory bodies have played a major role in the progress of this market through establishing defined guidelines for conducting PK studies. There are a substantial number of CROs engaged in conducting PK studies in accordance with relevant EMEA, ICH, FDA, GCP, and other regulatory guidelines.

Growing concern for effective implementation of PK services in the drug development process is anticipated to drive investments in this sector. Several conferences and certification courses are being conducted across the world to increase the understanding of various paradigms associated with pharmacokinetics application in clinical and preclinical drug development.

Pharmacokinetics Services Market Report Highlights:

  • Based on drug type, Small molecule dominated the market with a revenue share of 76.7% in 2022 and is expected to maintain its lead during the forecast period fueled by high service penetration and growing popularity of generics
  • PK analysis for large molecules are expected to grow significantly during the forecast period, driven by presence of significant number of biologics and biosimilars in the clinical development phase
  • Presence of a large number of biopharmaceutical and pharmaceutical manufacturing entities in U.S. has resulted in North America accounting for the largest share in 2022
  • Asia Pacific is estimated to expand at the fastest CAGR of 9.2% over the forecast period thanks to constant economic growth in several countries, which has attracted significant attention from global CROs and resulted in business expansions
  • Pharmaceutical Product Development, LLC; Charles River Laboratories International, Inc.; PAREXEL International Corporation; and Eurofins Scientific, Inc. are some of the key service providers
  • These CROs are undertaking various initiatives in order to capitalize on new market avenues and enhance their share in the future market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Type
    • 1.1.2. Application
    • 1.1.3. End use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmacokinetic Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Pharmacokinetic Services Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Pharmacokinetic Services Market: Drug Type Estimates & Trend Analysis

  • 4.1. Pharmacokinetic Services Market, Key Takeaways
  • 4.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Small Molecule
    • 4.3.1. Small molecule market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Large Molecules (Biopharmaceuticals)
    • 4.4.1. Large molecule (biopharmaceuticals) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Pharmacokinetic Services Market: Application Estimates & Trend Analysis

  • 5.1. Pharmacokinetic Services Market, Key Takeaways
  • 5.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Small and Medium Enterprise
    • 5.3.1. Small and medium enterprise market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Large Enterprise
    • 5.4.1. Large enterprise market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Pharmacokinetic Services Market: End Use Estimates & Trend Analysis

  • 6.1. Pharmacokinetic Services Market, Key Takeaways
  • 6.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Biotechnology & Pharmaceutical Companies
    • 6.3.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Academic & Government Research Institutes
    • 6.4.1. Academic & government research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Pharmacokinetic Services Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Pharmacokinetic Services Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Denmark
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Evotec AG
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Certara, L.P.
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Pacific BioLabs
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. GVK Biosciences Private Limited
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Shanghai Medicilon Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pharmaceutical Product Development, LLC
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Charles River Laboratories International, Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. PAREXEL International Corporation
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Eurofins Scientific, Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Frontage Labs
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. SGS SA
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. LGC Limited
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Creative Bioarray
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 3 North America pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 5 North America pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 U.S. pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Canada pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Europe pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 14 Europe pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Germany pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 UK pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 21 UK pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 France pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 24 France pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 Italy pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Spain pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 Denmark pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 Sweden pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Norway pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 44 Japan pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 45 Japan pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 46 Japan pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 48 China pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 49 China pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 India pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 52 India pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 53 Australia pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 54 Australia pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 55 Australia pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Thailand pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 57 Thailand pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 58 Thailand pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Korea pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 South Korea pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 61 South Korea pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 63 Latin America pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 67 Brazil pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 70 Mexico pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 73 Argentina pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 80 South Africa pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 86 UAE pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Pharmacokinetic services: Market outlook
  • Fig. 9 Pharmacokinetic services Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Pharmacokinetic services market driver impact
  • Fig. 15 Pharmacokinetic services market restraint impact
  • Fig. 16 Pharmacokinetic services market strategic initiatives analysis
  • Fig. 17 Pharmacokinetic services market: Drug type movement analysis
  • Fig. 18 Pharmacokinetic services market: Drug type outlook and key takeaways
  • Fig. 19 Small molecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Large molecules (biopharmaceuticals) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Pharmacokinetic services market: Application movement analysis
  • Fig. 22 Pharmacokinetic services market: Application outlook and key takeaways
  • Fig. 23 Small and medium enterprise market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Large enterprise market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Pharmacokinetic services market: End use movement analysis
  • Fig. 26 Pharmacokinetic services market: End use outlook and key takeaways
  • Fig. 27 Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Academic & government research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Global pharmacokinetic services market: Regional movement analysis
  • Fig. 31 Global pharmacokinetic services market: Regional outlook and key takeaways
  • Fig. 32 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)